巨子生物发布24 年财务报告：1）2024 年：公司24 年营业收入55.4 亿元，YOY+57%；经调整净利润21.5 亿元，YOY+46.5%。2）24H2： 24 年下半年公司营收29.8 亿元, YOY+57.7%，经调整净利润11.2 亿元, YOY+42%。收入拆分：可复美维持高增长，可丽金24H2 提速。1）按照品牌拆分：可复美24 年收入45.4 亿元，YOY+62.9%。可丽金...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.